Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
ALK Inhibitors for Acquired Resistance_ Zykadia and Alectinib [720p](1)
